Rufinamide

證據等級: L5

預測適應症: 5 個

One-Sentence Summary

Rufinamide is a triazole-derivative anticonvulsant, publicly known as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome; no Taiwan-specific approved indication text is available in this evidence pack. The TxGNN model predicts it may be effective for Febrile Infection-Related Epilepsy Syndrome (FIRES), a rare and severe epileptic encephalopathy. Currently, 0 clinical trials and 0 publications support this specific direction — this is a model-prediction-only candidate.

Quick Overview

Item	Content
Original Indication	Not available from Taiwan regulatory data (drug not marketed in Taiwan). Publicly known global indication: Lennox-Gastaut Syndrome (adjunctive therapy)
Predicted New Indication	Febrile Infection-Related Epilepsy Syndrome (FIRES)
TxGNN Prediction Score	99.57%
Evidence Level	L5 (model prediction only, no clinical or literature evidence)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on generally known information, rufinamide is a triazole-derivative antiepileptic drug that modulates voltage-gated sodium channels, prolonging their inactive state and limiting repetitive neuronal firing. It is broadly recognized as an adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome, a severe, treatment-resistant childhood epileptic encephalopathy.

FIRES, the top-ranked predicted indication, is likewise a rare and catastrophic epileptic encephalopathy characterized by refractory status epilepticus following a febrile illness. Mechanistically, both conditions involve widespread cortical hyperexcitability that is poorly controlled by conventional first-line anticonvulsants, which provides a plausible biological rationale for testing broad-spectrum sodium-channel modulators such as rufinamide in FIRES.

That said, this rationale is currently supported only by TxGNN’s knowledge-graph inference (score 99.57%, rank 10564) — there are no registered clinical trials, ICTRP entries, or published literature in this evidence pack that directly evaluate rufinamide in FIRES. The prediction should be interpreted as a hypothesis-generating signal rather than clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

No license records are available. The evidence pack indicates rufinamide currently has 0 approved licenses and is not marketed in Taiwan (TFDA); a formal safety review is blocked pending retrieval of the package insert (see Data Gap DG001).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (FIRES) is currently supported only by a TxGNN model score with no corroborating clinical trials or literature (Evidence Level L5), and critical safety data (TFDA warnings/contraindications, mechanism of action) are marked as blocking data gaps. Proceeding to any evaluation stage beyond S0 is not appropriate at this time.

To proceed, the following is needed:

TFDA (or originator) package insert — warnings, contraindications, DDI profile (Data Gap DG001, Blocking)
Confirmed mechanism of action detail from DrugBank or primary pharmacology literature (Data Gap DG002)
Targeted literature/case-report search specifically on rufinamide use in FIRES or related refractory status epilepticus syndromes
Monitoring of clinicaltrials.gov / ICTRP for any newly registered trials in this indication

Note: TxGNN also flagged four additional rare epilepsy syndromes (perioral myoclonia with absences, photosensitive occipital lobe epilepsy, cryptogenic late-onset epileptic spasms, atypical childhood epilepsy with centrotemporal spikes) as lower-ranked candidates — all similarly at Evidence Level L5 / Stage S0 / Hold, with no supporting clinical or literature evidence.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.